3.04
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Premarket
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Personalis Inc | PSNL | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 3.04 | 04:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.04 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 1.73 - 12.96 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 3.04 | USD |
Period:
Draw Mode:
Personalis Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 139.75M | 45.97M | 27.89M | $ 85.49M | $ -69.70M | -1.49 | -1.10 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | -31.31k | 2.60% |
Personalis News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PSNL Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.21 | 3.11 | 2.19 | 2.69 | 352,419 | 0.83 | 37.56% |
| 1 Month | 2.20 | 3.11 | 1.97 | 2.50 | 333,115 | 0.84 | 38.18% |
| 3 Months | 2.52 | 3.11 | 1.73 | 2.38 | 370,460 | 0.52 | 20.63% |
| 6 Months | 4.10 | 5.575 | 1.73 | 3.00 | 390,157 | -1.06 | -25.85% |
| 1 Year | 11.37 | 12.96 | 1.73 | 4.65 | 468,033 | -8.33 | -73.26% |
| 3 Years | 10.92 | 53.46 | 1.73 | 18.36 | 544,447 | -7.88 | -72.16% |
| 5 Years | 23.70 | 53.46 | 1.73 | 17.98 | 521,091 | -20.66 | -87.17% |
Personalis Description
| Personalis Inc is a provider of advanced genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Liquid Biopsy, NeXT Dx Test, and other Pharma Research Solutions. |
